Key result
Elevated baseline circulating adipocyte fatty acid-binding protein (AFABP) independently predicted incident major adverse cardiovascular events (HR 2.65) and worsening of left ventricular remodelling.
Why the study?
Prior cross-sectional studies evaluating the relationship between adipocyte fatty acid-binding protein and cardiac remodelling showed conflicting results, prompting prospective evaluation of longitudinal changes in type 2 diabetes mellitus.
Does elevated baseline adipocyte fatty acid-binding protein (AFABP) predict adverse left ventricular remodeling, diastolic dysfunction, and incident MACE in patients with type 2 diabetes without baseline cardiovascular disease?
Cohort (n=176)
No
Does elevated baseline adipocyte fatty acid-binding protein (AFABP) predict adverse left ventricular remodeling, diastolic dysfunction, and incident MACE in patients with type 2 diabetes without baseline cardiovascular disease?
Answers are grounded in this paper and cite their sources.
Elevated circulating AFABP levels independently predict adverse left ventricular remodeling, diastolic dysfunction, and incident cardiovascular events in patients with type 2 diabetes without prior cardiovascular disease.
BACKGROUND: The relationship between adipocyte fatty acid-binding protein (AFABP) and cardiac remodelling has been reported in cross-sectional studies, although with conflicting results. Type 2 diabetes mellitus (T2DM) is associated with left ventricular (LV) hypertrophy and diastolic dysfunction, as well as elevated circulating AFABP levels. Here we investigated prospectively the association between AFABP with the longitudinal changes of cardiac remodelling and diastolic dysfunction in T2DM. METHODS: Circulating AFABP levels were measured in 176 T2DM patients without cardiovascular diseases (CVD) at baseline. All participants received detailed transthoracic echocardiography both at baseline and after 1 year. Multivariable linear and Cox regression analyses were used to evaluate the associations of circulating AFABP levels with changes in echocardiography parameters and incident major adverse cardiovascular events (MACE), respectively. RESULTS: The median duration between baseline and follow-up echocardiography assessments was 28 months. Higher sex-specific AFABP quartiles at baseline were associated with increase in LV mass and worsening of average E/e' (all P < 0.01). Multivariable linear regression demonstrated that AFABP in the highest quartile was independently associated with both increase in LV mass (β = 0.89, P < 0.01) and worsening of average E/e' (β = 0.57, P < 0.05). Moreover, multivariable Cox regression analysis showed that elevated baseline circulating AFABP level independently predicted incident MACE (HR 2.65, 95% CI 1.16-6.05, P < 0.05) after adjustments for age, sex, body mass index, glycated haemoglobin, hypertension, dyslipidemia and presence of chronic kidney disease. CONCLUSION: Circulating AFABP level at baseline predicted the development of LV hypertrophy, diastolic dysfunction and MACE in T2DM patients without CVD.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2020) conducted a cohort in Type 2 diabetes mellitus without cardiovascular disease (n=176). Elevated circulating adipocyte fatty acid-binding protein (AFABP) vs. Lower AFABP quartiles was evaluated on Incident major adverse cardiovascular events (MACE) (HR 2.65, 95% CI 1.16-6.05, p=<0.05). Elevated baseline circulating adipocyte fatty acid-binding protein (AFABP) independently predicted incident major adverse cardiovascular events (HR 2.65) and worsening of left ventricular remodelling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: